TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19652059

Group type: EXPERIMENTAL
Intervention: Pomalidomide (2 mg/d) plus placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pomalidomide (2 mg/d) plus prednisone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pomalidomide (0.5 mg/d) plus prednisone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Prednisone plus placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pomalidomide (2 mg/d) plus placebo (n = 62 patients receiving > or = 3 cycles)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pomalidomide (2 mg/d) plus prednisone (n = 62 patients receiving > or = 3 cycles)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pomalidomide (0.5 mg/d) plus prednisone (n = 62 patients receiving > or = 3 cycles)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Prednisone plus placebo (n = 62 patients receiving > or = 3 cycles)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pomalidomide therapy (0.5 or 2 mg/d) with or without prednisone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 84
Study: 18261356

Group type: EXPERIMENTAL
Intervention: MCAS group (based on TCD examination)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: MCAS group
Number of subjects: 1068

Group type: COMPARATOR
Intervention: non-MCAS group
Number of subjects: 1068
Study: 14712348

Group type: EXPERIMENTAL
Intervention: 20% dextrose (study iii)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intralipid and heparin (study ii)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intralipid and heparin combined with 20% dextrose (study iv)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal saline (study i)
Number of subjects: 8
Study: 11165419

Group type: EXPERIMENTAL
Intervention: Community-based recruitment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital-based recruitment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall screening and recruitment
Number of subjects: 0
Study: 10730110

Group type: EXPERIMENTAL
Intervention: 330 mL beer (containing about 20 g ethanol)
Number of subjects: 52
Study: 9135531

Group type: EXPERIMENTAL
Intervention: Oral dietary supplements during inpatient phase
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (normal ward diet) during inpatient phase
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral dietary supplements during outpatient phase
Number of subjects: 100
Study: 1901332

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (rIFN-gamma) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7041652

Group type: EXPERIMENTAL
Intervention: Cefoxitin (3 doses of 2 gm each)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 266
Study: 31933417

Group type: EXPERIMENTAL
Intervention: Secondary cytoreduction surgery (SCS)
Number of subjects: 62
Study: 31050066

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation pre-exercise (WP-PLA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation post-exercise (PLA-WP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (PLA-PLA)
Number of subjects: 70
Study: 28524243

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (SDR) in bulk increments of up to 4 mm
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional 2-mm resin composite layering technique
Number of subjects: 38
Study: 25824424

Group type: EXPERIMENTAL
Intervention: Escitalopram, Sertraline, Venlafaxine-XR (SSRIs and SNRIs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-responders to Venlafaxine-XR
Number of subjects: 80

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 80
Study: 23160149

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 106
Study: 22008366

Group type: EXPERIMENTAL
Intervention: Community health centres (salary-based physicians)
Number of subjects: 4808

Group type: EXPERIMENTAL
Intervention: Blended capitation practices
Number of subjects: 4808

Group type: COMPARATOR
Intervention: Fee-for-service practices
Number of subjects: 4808
Study: 18450847

Group type: EXPERIMENTAL
Intervention: Community-based kangaroo mother care
Number of subjects: 4165

Group type: COMPARATOR
Intervention: Control group (no community-based kangaroo mother care)
Number of subjects: 4165
Study: 17048428

Group type: EXPERIMENTAL
Intervention: High dose oral vitamin B6 (50 mg), vitamin B12 (1 mg), and folic acid (15 mg) daily for 6 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oral 5 mg folic acid alone for 6 months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High dose oral vitamin B6, vitamin B12, and folic acid
Number of subjects: 54
Study: 12612510

Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclip placement
Number of subjects: 79

Group type: COMPARATOR
Intervention: Distilled water injection
Number of subjects: 79
Study: 10984820

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8689841

Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycaemia (blood glucose 2.5 ± 0.4 mmol l-1 for 62 ± 8 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycaemia
Number of subjects: 10
Study: 2062511

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg per day)
Number of subjects: 3711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3711
Study: 6660476

Group type: EXPERIMENTAL
Intervention: diazepam 10 mg/70 kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: flunitrazepam 1 mg/70 kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: fentanyl 0.15 mg/70 kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study: 30785358

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a (control)
Number of subjects: 1485
Study: 29741714

Group type: EXPERIMENTAL
Intervention: Enriching early-life activities score
Number of subjects: 93
Study: 29148881

Group type: EXPERIMENTAL
Intervention: 32 mg of buprenorphine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 64 mg of buprenorphine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 96 mg of buprenorphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 26422298

Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg and mirabegron 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg and mirabegron 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapies (solifenacin and mirabegron)
Number of subjects: 0
Study: 23765449

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System (IVRS) version of the EORTC QLQ-C30
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper version of the EORTC QLQ-C30
Number of subjects: 0
Study: 22244743

Group type: EXPERIMENTAL
Intervention: bevacizumab-CP
Number of subjects: 180

Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 180
Study: 19173747

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program informed by a participant preferences questionnaire
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual exercise prescription (without preferences questionnaire)
Number of subjects: 150
Study: 17929306

Group type: EXPERIMENTAL
Intervention: CPG 10101 at 0.75 mg/kg SC once weekly for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CPG 10101 (doses >/= 1 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CPG 10101
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15178658

Group type: EXPERIMENTAL
Intervention: Cervical dilatation before embryo transfer
Number of subjects: 283

Group type: COMPARATOR
Intervention: No cervical dilatation
Number of subjects: 283
Study: 12492614

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (75 mg kg‐1 day‐1, 25 mg kg‐1 every 8 h)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 9816718

Group type: EXPERIMENTAL
Intervention: ondansetron 0.1 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 80
Study: 8867566

Group type: EXPERIMENTAL
Intervention: Isradipine + Captopril
Number of subjects: 368

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368

Group type: COMPARATOR
Intervention: Normotensives
Number of subjects: 368
Study: 2572184

Group type: EXPERIMENTAL
Intervention: Rapid bolus injection of vecuronium bromide (0.015 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow infusion of vecuronium bromide (0.015 mg/kg) over 5 min
Number of subjects: 0
Study: 52050

Group type: EXPERIMENTAL
Intervention: Streptokinase and plasminogen infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Streptokinase infusion only (Control)
Number of subjects: 17
Study: 31039826

Group type: EXPERIMENTAL
Intervention: Spermidine supplementation for 12 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 100
Study: 28532439

Group type: EXPERIMENTAL
Intervention: Oncokompas eHealth self-management application
Number of subjects: 544

Group type: COMPARATOR
Intervention: Care as usual (wait-list control group)
Number of subjects: 544
Study: 25200983

Group type: EXPERIMENTAL
Intervention: Manual brushing (G1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electric toothbrush on (G2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electric toothbrush off (G3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between G1 and G3
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between G2 and G3
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between G1 and G2
Number of subjects: 40
Study: 23701274

Group type: EXPERIMENTAL
Intervention: Benfotiamine (900 mg/day for 6 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 22178840

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ultrasonic subgingival scaling and root planing with hand instrument (SRP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment for sites with PD≥4 mm
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional SRP for sites with PD≥4 mm
Number of subjects: 17
Study: 18851769

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behaviour (TPB) intervention targeting subjective norms through an interactive educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control site (no specific intervention mentioned)
Number of subjects: 0
Study: 16252275

Group type: EXPERIMENTAL
Intervention: Conditional Markov model with non-ignorable dropout component
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Applications to a data set from a parasitic field infection survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Applications to a data set from a cocaine treatment study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Applications to a data set from an aging study
Number of subjects: 0
Study: 15209771

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (60, 90, 120, 150 U)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Subcutaneous (s.c.) injected regular human insulin (8, 14, or 20 U)
Number of subjects: 13
Study: 11424544

Group type: EXPERIMENTAL
Intervention: 200 mg ginseng
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 400 mg ginseng
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 83
Study: 9421749

Group type: EXPERIMENTAL
Intervention: Interactions with deviant child confederates (ADHD, CD, ODD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exposure to deviant child confederates
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interactions with normal child confederates
Number of subjects: 60
Study: 8252786

Group type: EXPERIMENTAL
Intervention: Calcipotriol alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calcipotriol plus occlusion
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Occlusion plus calcipotriol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Occlusion plus placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calcipotriol plus occlusion vs Calcipotriol alone
Number of subjects: 48
Study: 3493465

Group type: EXPERIMENTAL
Intervention: Low intensity TENS at 100 Hz for 30 min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 11
Study: 31837209

Group type: EXPERIMENTAL
Intervention: Vitamin D2 (tVDD)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (pVDD)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-vitamin D deficient (nVDD)
Number of subjects: 84
Study: 29650205

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline solution gargling
Number of subjects: 44
Study: 27986077

Group type: EXPERIMENTAL
Intervention: Peer support with weekly home-visits
Number of subjects: 640

Group type: COMPARATOR
Intervention: First-line ART regimens according to the National Treatment Guidelines (Control)
Number of subjects: 640
Study: 24326237

Group type: EXPERIMENTAL
Intervention: Home-based behavioral management training (BMT)
Number of subjects: 127
Study: 22443163

Group type: EXPERIMENTAL
Intervention: Short-stay ventilation tubes
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Adenoidectomy with short-stay ventilation tubes
Number of subjects: 376

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 376
Study: 20872115

Group type: EXPERIMENTAL
Intervention: Extracorporeal high frequency thermotherapy (EHFT) combined with Chinese medicine (CM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chinese medicine (CM) only
Number of subjects: 66
Study: 18827047

Group type: EXPERIMENTAL
Intervention: Personal Contact (PC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive Technology (IT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-directed usual care (SD)
Number of subjects: 0
Study: 15635110

Group type: EXPERIMENTAL
Intervention: Intensive treatment (80 mg of atorvastatin orally per day)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Moderate treatment (40 mg of pravastatin orally per day)
Number of subjects: 502
Study: 14658375

Group type: EXPERIMENTAL
Intervention: Type 3 tennis ball
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular size tennis ball
Number of subjects: 16
Study: 10405544

Group type: EXPERIMENTAL
Intervention: Midfinger smears
Number of subjects: 69
Study: 8543970

Group type: EXPERIMENTAL
Intervention: Intravenous PCNU
Number of subjects: 311

Group type: COMPARATOR
Intervention: Intra-arterial cisplatin
Number of subjects: 311
Study: 2135030

Group type: EXPERIMENTAL
Intervention: Subcutaneous PCA with oxymorphone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Subcutaneous PCA with morphine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous PCA with oxymorphone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous PCA with morphine
Number of subjects: 120
Study: 365313

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (800-1200 mg/m2 iv q 3 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Combination of Adriamycin (30-50 mg/m2 iv Day 1), 5-Fluorouracil (400-500 mg/m2 iv Day 1, 8), and Cyclophosphamide (150-200 mg/m2 po Day 3-6)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 27

Group type: COMPARATOR
Intervention: Combination treatment
Number of subjects: 27
Study: 30901428

Group type: EXPERIMENTAL
Intervention: adaptive CBT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: non-adaptive CBT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: adaptive simulator
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: non-adaptive simulator
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: lecture
Number of subjects: 92
Study: 29133942

Group type: EXPERIMENTAL
Intervention: ns1 gene (100 µg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: vp3 gene (100 µg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ns1 + vp3 gene combination (100 µg each)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Negative control (base values before therapy)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Positive control (after complete remission)
Number of subjects: 18
Study: 25384968

Group type: EXPERIMENTAL
Intervention: Orthogonal injection of 0.05 mL of bevacizumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oblique injection of 0.05 mL of bevacizumab
Number of subjects: 10
Study: 24070635

Group type: EXPERIMENTAL
Intervention: Exercise interventions (specific types not detailed)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 261
Study: 21440505

Group type: EXPERIMENTAL
Intervention: 3 months NADT plus radiotherapy
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: 6 months NADT plus radiotherapy
Number of subjects: 802

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 802
Study: 18270842

Group type: EXPERIMENTAL
Intervention: Dopamine agonists
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (similar age distribution)
Number of subjects: 50
Study: 17069269

Group type: EXPERIMENTAL
Intervention: Transmural Care Model for Multiple Sclerosis
Number of subjects: 173

Group type: COMPARATOR
Intervention: Traditional care as usual
Number of subjects: 173
Study: 12879082

Group type: EXPERIMENTAL
Intervention: Isolated soy protein
Number of subjects: 18

Group type: COMPARATOR
Intervention: Caseinate
Number of subjects: 18
Study: 11083409

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alpha-blocker treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 0
Study: 9118031

Group type: EXPERIMENTAL
Intervention: HCVAb positive groups (I and IV)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Group II (HBsAg[+], HCVAb[‐])
Number of subjects: 202

Group type: COMPARATOR
Intervention: HCVAb negative groups (II and III)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: HCV-related HCC
Number of subjects: 202
Study: 1731289

Group type: EXPERIMENTAL
Intervention: Oral sulindac for 48 hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral indomethacin for 48 hours
Number of subjects: 36
Study: 2862318

Group type: EXPERIMENTAL
Intervention: Multipuncture skin test with excretory-secretory (ES) toxoplasma antigen
Number of subjects: 414

Group type: COMPARATOR
Intervention: Indirect fluorescent antibody (IFA) test
Number of subjects: 414
Study: 30872538

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: No treatment or placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Screening programs
Number of subjects: 15
Study: 29020818

Group type: EXPERIMENTAL
Intervention: Juvenile Justice Anger Management (JJAM) Treatment for Girls
Number of subjects: 57
Study: 27634090

Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration during bipedal stance on foam with eyes closed
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Achilles tendon vibration during bipedal stance on BOSU
Number of subjects: 20
Study: 24955858

Group type: EXPERIMENTAL
Intervention: 24h on-call shift (OCD)
Number of subjects: 30
Study: 22001024

Group type: EXPERIMENTAL
Intervention: Combined implementation intention
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Separate implementation intentions
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Target strategies
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Preparatory strategies
Number of subjects: 580

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 580
Study: 19967530

Group type: EXPERIMENTAL
Intervention: 0.6-g/kg dose of ethanol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Future event simulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 32
Study: 17009633

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - Group 1 (first dose)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - Group 2 (second dose)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 106
Study: 14558587

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 1.5 mg/kg injected over 2 minutes with propofol 0.4 mg/kg and continuous infusion of propofol 3 mg/kg/h.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline placebo solution with propofol 0.4 mg/kg and continuous infusion of propofol 3 mg/kg/h.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol with propofol.
Number of subjects: 45
Study: 11140428

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via Diskhaler
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via Diskus
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via Metered-Dose Inhaler (MDI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) via all devices
Number of subjects: 12
Study: 9547133

Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg single dose, followed by 150 mg three times a day for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (single blind)
Number of subjects: 15
Study: 8436154

Group type: EXPERIMENTAL
Intervention: NTG 0.5 microgram.kg‐1 x min‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 6
Study: 3787644

Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.16 ppm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.14 ppm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.12 ppm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.10 ppm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ozone exposure at 0.08 ppm
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ozone exposure at 0.00 ppm (control)
Number of subjects: 24